Advertise on podcast: VJNeurology Podcast

This episode of the VJNeurology podcast explores the evolving role of Bruton’s tyrosine kinase (BTK) inhibitors in the treatment of multiple sclerosis (MS), from the role of BTK in MS pathophysiology to the recent EU approval of tolebrutinib for secondary progressive MS without relapses. Experts discuss the pivotal Phase III HERCULES (NCT04411641) and GEMINI (NCT04410978) trial data supporting tolebrutinib, alongside findings from the Phase III FENtrepid trial (NCT04544449) of fenebrutinib, a non-covalent BTK inhibitor, in primary progressive MS. Featuring Augusto Miravalle, MD, FAAN, Rush University Medical College, Chicago, IL, Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, Anthony Traboulsee, MD, University of British Columbia, Vancouver, Canada, and Amit Bar-Or, MD, FRCPC, University of Pennsylvania, Philadelphia, PA.

In this episode, we explore the relationship between menopause and neurological conditions, and consider how hormonal changes during the menopause transition may influence symptoms, disease management, and brain health. Katarina Rukavina, MD, PhD, Movement Disorders Hospital, Beelitz, Germany, discusses the management of menopause in patients with Parkinson's disease, followed by Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, who focuses on multiple sclerosis. Finally, Amber Watts, PhD, University of Kansas, Lawrence, KS, shares insights into the relationship between hormonal changes, cognition, and Alzheimer's disease.

In this episode, we bring you a discussion recorded at EAN 2026 exploring the growing impact of climate change on neurological health. The panel discusses evidence linking rising temperatures and environmental change with worsening neurological conditions, increased risk of heat-related illness, and implications for mental health. The discussion also highlights the importance of advocacy, education, and policy action, with a call for neurologists worldwide to work together to protect vulnerable patients and address the neurological consequences of a changing climate. Featuring Jacques Reis, MD, PhD, University of Strasbourg, Strasbourg, France, Anne-Marie Landtblom, MD, PhD, Uppsala University, Uppsala, Sweden, Pascale Homeyer, MD, Valence Hospital, Valence, France, Thomas Berger, MD, MSc, FEAN, Medical University of Vienna, Vienna, Austria, David Tanner, Msc ETH, University of Bern, Bern, Switzerland, Amalia Ghergu, MD, Hospital Center De Sens, Sens, France.

Welcome to this episode of the VJNeurology Podcast, where leading experts will explore some of the latest advances in the treatment of myasthenia gravis, discussing emerging therapeutic strategies and new clinical data that could shape the future management of this condition. You'll hear about recently approved therapies, including inebilizumab and nipocalimab, as well as promising approaches still in development, such as CAR T-cell therapy and telitacicept. Featuring Richard Nowak, MD, MS, Yale School of Medicine, New Haven, CT, and Ali Habib, MD, University of California, Irvine, CA.

Episode 2 of our Life after Stroke roundtable discussion series is now available as a podcast! In this exclusive discussion, leading experts Aristeidis Katsanos, MD, PhD, McMaster University, Hamilton, Canada, Hanne Christensen, MD, PhD, Bispebjerg Hospital, Copenhagen, Denmark, Joseph Kwan, MB ChB, MPhil, MD, Charing Cross Hospital, London, UK, and Jesse Dawson, MD, University of Glasgow, Glasgow, UK, discuss practical strategies for secondary stroke prevention and rehabilitation. They share insights into anti-thrombotic therapies, lipid-lowering, and blood pressure management, as well as real-world implementation strategies and the importance of lifestyle interventions. This educational activity has received independent medical education support in the form of funding from Bayer. The supporter has had no influence over the production of the content, including the selection of speakers. Bayer’s support is limited to this activity and does not extend to the broader Stroke Channel.

In this episode of the VJNeurology Podcast, we explore the rapidly evolving landscape of orexin agonists for the treatment of narcolepsy. Following the recent FDA approval of oveporexton, as well as new clinical trial data on alixorexton and E2086, experts discuss the latest evidence, emerging developments, and what these advances could mean for the future of narcolepsy treatment. Featuring Nancy Foldvary-Schaefer, DO, Cleveland Clinic, Cleveland, OH, Emmanuel Mignot, MD, PhD, Stanford University School of Medicine, Palo Alto, CA, Lucie Barateau, MD, PhD, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, France, and Bruce Corser, MD, FAASM, Intrepid Research, Cincinnati, OH.

Episode 1 of our Life after Stroke roundtable discussion series is now available as a podcast! In this exclusive discussion, leading experts Aristeidis Katsanos, MD, PhD, McMaster University, Hamilton, Canada, Diana Aguiar de Sousa, MD, PhD, Central Lisbon University Hospital Center, Lisbon, Portugal, Jesper Petersson, MD, PhD, Lund University, Lund, Sweden, and Gisele Sampaio Silva, MD, PhD, Federal University of São Paulo, São Paulo, Brazil, explore the first steps in secondary stroke prevention. They discuss the impact of recurrent stroke on patient outcomes, identify populations at highest risk, and examine key modifiable risk factors. The panel also shares practical insights on what should be prioritized during the early assessment of patients following stroke. This educational activity has received independent medical education support in the form of funding from Bayer. The supporter has had no influence over the production of the content, including the selection of speakers. Bayer’s support is limited to this activity and does not extend to the broader Stroke Channel.

This episode of the VJNeurology Podcast showcases advances across insomnia, restless legs syndrome, narcolepsy, and sleep apnea from SLEEP 2026. Leading experts discuss updates to the American Academy of Sleep Medicine clinical practice guidelines, trial updates, novel approaches being explored, and more. Featuring insights from Emerson Wickwire, PhD, University of Maryland, Baltimore, MD, Michael Mak, MD, FRCPC, DRCPSC, FCPA, FAASM, University of Toronto, Toronto, Canada, Michael Grandner, PhD, University of Arizona, Tucson, AZ, Diego Garcia-Borreguero, MD, PhD, Sleep Research Institute, Madrid, Spain, Arthur Walters, MD, Vanderbilt University Medical Center (VUMC), Nashville, TN, Nancy Foldvary-Schaefer, DO, Cleveland Clinic, Cleveland, OH, Lucie Barateau, MD, PhD, Gui-de-Chauliac Hospital, CHU Montpellier, Montpellier, France, Atul Malhotra, MD, University of California San Diego, San Diego, CA, Karin Johnson, MD, Baystate Medical Center, Springfield, MA, and Umakanth Katwa, MD, Boston Children’s Hospital, Boston, MA.

This episode of the VJNeurology Podcast showcases key trial updates from the American Academy of Neurology Annual Meeting in Chicago, IL. Highlights include orexin receptor agonists for narcolepsy, AMT‑130 in Huntington’s disease, ulixacaltamide for essential tremor, ecopipam for Tourette’s, novel headache agents, and more. Featuring Emmanuel Mignot, MD, PhD, Stanford University School of Medicine, Palo Alto, CA, Bruce Corser, MD, FAASM, Intrepid Research, Cincinnati, OH, Victor Sung, MD, University of Alabama, Birmingham, AL, Kinga Tomczak, MD, PhD, Boston Children’s Hospital, Boston, MA, Peter Goadsby, MD, PhD, DSc King Abdullah University of Science and Technology (KAUST, Thuwal, Saudi Arabia, Amy Waldman, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, Patricia Coyle, MD, Stony Brook Medicine, Lake Grove, NY, Defne Amado, MD, PhD, University of Pennsylvania, Philadelphia, PA, and Jill Farmer, DO, MPH, Drexel University College of Medicine, Philadelphia, PA.

This episode of the VJNeurology Podcast features a discussion with Prof. Karen Spruyt, PhD, Université Paris Cité, INSERM, NeuroDiderot, Paris, on pediatric sleep disturbances. Prof. Spruyt shares her expert perspectives on the impact of sleep disturbances in children, how to screen for these disturbances, and ongoing research in the field.

This episode focuses on key updates in multiple sclerosis (MS) research from the 11th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. We begin with key trial updates, including the FENtrepid (NCT04544449) and MoonStone (NCT06564311) results presented by Amit Bar-Or, MD, FRCPC, University of Pennsylvania, Philadelphia, PA. Le Hanh Hua, MD, Cleveland Clinic, Las Vegas, NV, then discusses a secondary analysis of the OLIKOS study (NCT04486716), and Jeffrey Cohen, MD, Cleveland Clinic, Cleveland, OH, introduces the use of hematopoietic stem cell transplantation.   Novel technologies are discussed by Gianmarco Bellucci, MD, PhD, University of California, San Francisco, CA, Raphael Schneider, MD, PhD, FRCPC, CIP, St. Michael’s Hospital, Toronto, Canada, and Valentina Fossati, PhD, The Jackson Laboratory, New York, NY. Finally, Gary Cutter, MS, PhD, UAB School of Public Health, Birmingham, AL, shares the limitations of using brain atrophy measured by MRI as a clinical trial endpoint, and Dalia Rotstein, MD, University of Toronto, Toronto, Canada, discusses a study that found that MS onset precedes EBV infection in some cases.

In this episode of the VJNeurology podcast, we are joined by Prof. Mona Nada, MBBCh, MD, Cairo University, Cairo, Egypt, to discuss updates in the prevention, diagnosis, and treatment of cluster headache. Cluster headache is a rare but devastating primary headache disorder, often described as one of the most severe pain conditions in medicine. Characterized by recurrent attacks of severe unilateral head pain, accompanied by autonomic symptoms such as lacrimation and nasal congestion, it has a profound impact on patients’ quality of life. Despite this, cluster headache remains under-recognised and challenging to treat, making ongoing research and expert clinical insight essential.

This episode of the VJNeurology Podcast focuses on the impact of climate change and temperature fluctuations on the management of epilepsy. Anita Arsovska, MD, PhD, University “Ss Cyril and Methodius”, Skopje, North Macedonia, and Medine Gulcebi Idriz Oglu, MD, Marmara University, Istanbul, Turkey, delve into the effects of rising temperatures on seizure frequency, the supply chains of anti-seizure medication, the stability of anti-seizure medication, and adverse reactions to medication.

In this episode of the VJNeurology Podcast, Jeffrey Dunn, MD, Stanford University School of Medicine, Palo Alto, CA, shares insights from a Phase I trial (NCT06138132) of CAR T-cell therapy for multiple sclerosis (MS). CAR T-cell therapy is a form of adoptive cell transfer that has revolutionized hematologic oncology and is now being investigated as a targeted immunotherapeutic approach for autoimmune diseases such as MS. Prof. Dunn will delve into the mechanism of action of CAR-T in MS and share findings from the trial.

In this episode of the VJNeurology Podcast, we’re joined by Krystof Bankiewicz, MD, PhD, The Ohio State University, Columbus, OH, to explore the evolving role of gene therapy in Parkinson’s disease and other neurological disorders. Dr Bankiewicz provides an insightful overview of gene therapies currently in clinical development, highlighting emerging efficacy and safety data from ongoing trials. He also delves into the selection of appropriate candidates for these treatments and discusses how close we are to translating these advances into routine clinical care.